David Drutz - Nov 18, 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Director
Signature
/s/ Richard Eisenstadt, as Attorney-in-Fact
Stock symbol
ALT
Transactions as of
Nov 18, 2022
Transactions value $
$334
Form type
4
Date filed
11/21/2022, 03:05 PM
Previous filing
Sep 30, 2022
Next filing
Mar 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $334 +139 +0.69% $2.40 20.2K Nov 18, 2022 Direct
holding ALT Common Stock, par value $0.0001 333 Nov 18, 2022 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Options Exercise $0 -139 -100% $0.00* 0 Nov 18, 2022 Common Stock, par value $0.0001 139 $2.40 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
F2 This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018.
F3 This option is fully vested and exercisable as of the date hereof.